MedPath
NMPA Approval

Adalimumab Solution for Injection

国药准字S20200020

September 2, 2020

Drug Information

阿达木单抗注射液

苏立信

注射剂

40mg(0.8ml)/瓶;40mg(0.8ml)/支(预充式注射器)

生物制品

September 2, 2020

Company Information

Applicant Company

苏州工业园区东平街168号

Manufacturing Company

苏州工业园区东平街168号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

阿达木单抗注射液 - NMPA 批准文号 | MedPath